Snotwatch: an ecological analysis of the relationship between febrile seizures and respiratory virus activity

Rana Sawires¹,²*, Martin Kuldořf³, Michael Fahey⁴,⁵, Hazel Clothier²,⁶ and Jim Buttery¹,²,⁷

Abstract

Background: Febrile seizures are the commonest type of seizure in occurring in the first few years of life, mostly affecting children aged six months to five years old. While largely benign, the incidence of each febrile seizure increases the risk of recurrence, afebrile seizures and epilepsy. Viruses are the most frequent cause of febrile illnesses in which a febrile seizure occurs. Febrile seizure presentation patterns appear to follow a seasonal trend.

Aims: To identify patterns of febrile seizure incidence across different seasons with specific viral activity, and to establish a framework for analysing virus circulation data with common illnesses within a shared region and population.

Setting: Our study was a study of febrile seizure presentations in Victoria, Australia and respiratory virus detection.

Participants: We obtained independent datasets of emergency department febrile seizure presentations at Monash Health and all respiratory multiplex PCR tests performed at Monash Health from January 2010–December 2019 to observe common trends in virus circulation and febrile seizure incidence.

Study design: Trends were studied temporally through mixed effects Poisson regression analysis of the monthly incidence of febrile seizures and the rate of positive PCR tests. Peak viral seasons (95th centile incidence) were compared to median viral circulation (50th centile incidence) to calculate peak season risk ratios.

Results: We found a 1.75–2.06 annual risk ratio of febrile seizure incidence in June–September. Temporal analysis of our data showed this peak in febrile seizures was attributable to circulating viruses in this season, and virus modelling showed correlation with increased rates of positive Influenza A (1.48 peak season risk ratio), Influenza B (1.31 peak season risk ratio), Human metapneumovirus (1.19 peak season risk ratio) and Respiratory Syncytial Virus (1.53 peak season risk ratio) on PCR testing.

Conclusion: Our ecological study statistically demonstrates the recognised winter peak in febrile seizure incidence and ascribes the seasonal relationship to several viral infections which affect the community, including a novel association with Human metapneumovirus.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Febrile seizures are the most common cause of seizure in childhood, with an incidence of 2–5% in North America and Europe [1–4]. They occur in the presence of a fever (>38°C) in children aged typically between 6 months and 5 years [5], where the seizure is not caused by an underlying central nervous system (CNS) infection or metabolic disturbance [5, 6]. Simple febrile seizures are single, generalised convulsions lasting less than 15 min. Complex febrile seizures comprise approximately 20–35% of all febrile seizures [7–10] and present with focal features, occur as clusters of episodes during a 24-h period or those that last for 15 min or more [5].

Viral infections are well-described as the predominant causative agents in febrile seizures, being detected in up to 82% of children with febrile seizures [10–14], although bacterial infections and vaccinations have been implicated in some cases [10, 15]. Further, the seasonality of febrile seizures, which peaks in fall and winter [16–18], supports their association with spikes in the incidence of upper respiratory tract infections (URTIs) and their causative viruses [3, 4, 13, 19–21]. Specific viruses have previously been implicated as the cause of febrile seizures, including Human Herpesvirus-6 (HHV-6) [22], Influenza A and B [20, 23], Respiratory syncytial virus (RSV) [24, 25], Parainfluenza [10, 13], Adenovirus [10, 26], Rhinovirus [11, 13] and Enterovirus [20].

Recent innovations in viral respiratory molecular diagnostics allow multiple viruses to be tested simultaneously using multiplex polymerase chain reaction (PCR) [27]. Given the known seasonal trends in prevalence for many common childhood viruses [13, 20, 23, 28–30], viral PCR data may be collated as ecologic data to track temporal viral activity in the community and explore the relationship of febrile seizures with common viral infections.

This study examined the temporal associations between organism epidemiology and health outcomes across south-eastern Melbourne. We aimed to identify patterns of febrile seizure incidence across different seasons with specific viral activity and provide insight into the impact of specific viruses on the frequency and severity of febrile seizure presentations. This technique potentially allows evaluation of the relationship between virus circulation and the burden of febrile seizures on the health system. These findings can, in turn, inform models addressing impact of therapies and vaccines against key viruses.

Methods

Study design and cohort

We conducted a retrospective ecologic cohort analysis of 10 years of data from 2010 to 2019. Independent, unlinked datasets from the same large hospital network health care provider were used to visualise and define associations between febrile seizures and virus activity. Monash Health is the largest health network in Victoria, Australia, based in south-east Melbourne, with three emergency departments caring for children and adults with more than 210,000 presentations annually [31]. Our inclusion criteria were all respiratory multiplex PCR assays from patients of all ages performed at Monash Health, and all febrile seizure presentations to Monash Health emergency departments recorded between 1st January 2010 and 31st December 2019. No patient records were available for analysis for patient de-identification. Therefore, the length of stay in the emergency department was used as a surrogate measure for the severity of the febrile seizure- febrile seizures with a stay of more than 4 hours duration were classified as “severe”.

Our exclusion criteria were febrile seizure presentations for patients >5 years old as febrile seizures are not diagnosed in children beyond this age [8].

Data collection

Emergency department (ED) febrile seizure presentation data were extracted from Monash Health business intelligence portal. Emergency department admissions with discharge diagnoses coded for febrile seizures (ICD-10-AM code R56.0) were obtained. Data extracted included: the patient’s age in years, gender, date of presentation and the length of stay in hours. Data were de-identified.

Respiratory multiplex PCR data were extracted through Monash Health pathology from the Medipath® system (LRS Health, Melbourne, Australia). This dataset included all respiratory PCRs performed from January 2010 to December 2019, irrespective of the result. Extracted data included: date of the test; the patient unit record number (URN); date of birth, gender, sampling site, and viruses detected on PCR. Data were de-identified before analysis.

Viruses included in the PCR assay were Influenza A and B, Parainfluenza 1, 2 and 3, Human metapneumovirus (hMPV), RSV, Adenovirus and Picornavirus.

Statistical analysis

The coding program, R (version 4.0.2) [32], was applied through RStudio (version 1.2.5) [33] for statistical analysis of temporal data. To account for the significant increase in the number of total PCR tests performed each year at our health service, viral incidence data were converted into a monthly rate.

We created two different models for our datasets, applying a mixed effect Poisson regression technique. The first model used the month of the year (MOY) as
an independent predictor of febrile seizures. This model
enabled us to determine the trend in febrile seizure pres-
sentations throughout the year. All risk ratios (RR) in
the MOY model were relative to the average number of
febrile seizures in April. We chose April as the reference
month because in Victoria, it coincides with the middle
of fall and was thus an appropriate centre between Win-
ter and Summer.

The second model was a multivariate model, using all
viruses as predictors of febrile seizures. This model ena-
bled us to ascertain which viruses were related to febrile
seizure presentations, thus explaining the observed sea-
sonal trends. For each virus, in any given month, the
number of positive tests was divided by the total number
of PCR tests performed during that month as per the fol-
lowing formula:

\[
\text{Monthly virus proportion for each virus} = \frac{\text{Monthly positive PCR tests for each virus}}{\text{Monthly total PCR tests performed}}
\]

We modelled the month of year and viruses separately
due to their collinearity; that is, months which were more
strongly associated with febrile seizure presentations
were likely associated due to higher levels of virus circu-
lation in those months.

The MOY and virus models were followed by subgroup
analysis, where models were created to explain the num-
ber of mild and severe febrile seizure presentations, and
the age groups (0–1 years, 1–2 years, 3–5 years) in which
febrile seizures presented.

We aimed to compare the influence of peak virus cir-
culation on febrile seizure presentations with the median
expected virus circulation. Thus, we compared the risk
of febrile seizures when viruses were present at or above
the 95th percentile of their maximum rate to the 50th
centile of their maximum rate. Our significance level was
set at \( p < 0.01 \).

Ethics approval
As per our study protocol (Appendix A), a waiver of
informed consent was sought, as all patient data was de-
identified and could not be traced back to the patients.
All methods for this ecological study were carried out in
accordance with the relevant guidelines and regulations.

The informed consent waiver was provided by Monash
Health Human Research Ethics Low Risk Panel, our pri-
mary Human Research Ethics Committee (HREC). This
was obtained beginning 24th July 2019 (NMA/ERM Refe-
rence Number: RES-19-000333-L-53611). See Appendix A.

Results
Cohort demographics

Febrile seizure cohort
There were a total of 4836 emergency department febrile
seizure presentations over the study period in children
aged 5 years or younger, equating to approximately 40.3
presentations of febrile seizures per month. Almost
half (46.3%) of all presentations were in one-year-old
(12–23 months) children and 24.6% in two-year-old (24–
35 months) children (see Appendix B.– Fig. 4 For the age
distribution of febrile seizure presentations).

Mild febrile seizure presentations (length of stay < 4h)
accounted for 78.1% of our cohort. Severe presentations
were more frequent in children under 1 year.

Respiratory multiplex PCR cohort
A total of 93,873 respiratory PCR tests were performed.
The number of tests performed each year increased sub-
stantially from 2010 to 2019 (Appendix C, Table 3). How-
ever, the annual proportion of viruses detected remained
approximately constant throughout the study period.
The majority of multiplex PCR assays (63%) were nega-
tive for all viruses tested, 26% detected one virus and 11%
detected 2 or more viruses.

Data visualisation
Many viruses demonstrated seasonal patterns with
winter peaks including RSV, Influenza and hMPV
(Fig. 1). A higher rate of positive PCR assays was
observed in 2010 and 2011 compared with subsequent
years. A clear winter peak was only observed in febrile
seizures occurring in children aged 1–2 years old, with
a less clear trend in 3-year-old children, and no dis-
tinguishable trends at the extremes of our cohort (in
children less than one, and in 5-year-old children).
(Appendix D, Fig. 5).

Febrile seizure association with season
More febrile seizure presentations occurred in May to
October compared to April. The greatest risk was in
the month of August where there was a 2.03 (99% CI
1.70–2.44) risk ratio of febrile seizure incidence. Fur-
thermore, January showed a reduced risk of febrile
seizure presentations (RR 0.72, 99% CI 0.57, 0.91). The
complete results of the monthly model are shown in
Table 1.
The monthly model showed the same increase in febrile seizures between May and October across all subgroups, except in children less than 1 year old.

**Table 1** Risk of ed. febrile seizure presentations by month of year

| Month       | Risk Ratio | 99% CI      | P-value |
|-------------|------------|-------------|---------|
| January     | 0.72       | 0.57, 0.91  | 0.0002  |
| February    | 0.86       | 0.69, 1.07  | 0.08    |
| March       | 0.94       | 0.76, 1.16  | 0.46    |
| April (Reference) | 1.00 | –          | –       |
| May         | 1.37       | 1.12, 1.66  | < 0.0001|
| June        | 1.76       | 1.46, 2.12  | < 0.0001|
| July        | 1.82       | 1.51, 2.19  | < 0.0001|
| August      | 2.03       | 1.70, 2.44  | < 0.0001|
| September   | 1.95       | 1.62, 2.34  | < 0.0001|
| October     | 1.38       | 1.14, 1.68  | < 0.0001|
| November    | 1.15       | 0.94, 1.41  | 0.071   |
| December    | 1.13       | 0.92, 1.39  | 0.12    |

This table shows the relative risk of febrile seizure presentations compared with April. At baseline, the Poisson model estimates 29.9 febrile seizure presentations in April, which was our reference month. Months with statistically significant risk ratios are denoted with *.

**Table 2** Risk of ed. febrile seizure presentations associated with respiratory viruses

| Virus   | 95% vs 50% Incidence Risk | 99% CI      | P-value |
|---------|----------------------------|-------------|---------|
| Adenovirus | 1.00                      | 0.93, 1.08  | 0.98    |
| hMPV*   | 1.19                      | 1.07, 1.33  | < 0.0001|
| Influenza A* | 1.48                    | 1.32, 1.67  | < 0.0001|
| Influenza B* | 1.31                    | 1.18, 1.46  | < 0.0001|
| Parainfluenza 1 | 0.94                    | 0.79, 1.12  | 0.35    |
| Parainfluenza 2 | 0.94                    | 0.85, 1.05  | 0.14    |
| Parainfluenza 3 | 1.06                    | 0.94, 1.19  | 0.25    |
| Picornavirus | 1.04                    | 0.92, 1.19  | 0.39    |
| RSV*    | 1.53                      | 1.38, 1.70  | < 0.0001|

Relative risk of febrile seizure incidence compared to a baseline incidence of 21.1 per month. Statistically significant risk ratios (p < 0.01) are denoted with *

Febrile seizure associations with viral circulation

Influenza A and B, hMPV and RSV were significantly associated with changes in febrile seizure incidence. The results of our model for the relationship between viruses and febrile seizures shown in Table 2.
Subgroup analysis did not yield any notable differences to the all-group febrile seizures analysis. The complete tables for the subgroup virus models are in Appendix E (Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13).

Discussion

This is the first ecologic study assessing febrile seizures with reference to contemporaneously collected multiplex viral respiratory samples from the same catchment population. We found that there was an increase in febrile seizures from May to October of each year compared to the risk of febrile seizure incidence in April, with the greatest risk in August. In Victoria, with a temperate climate, this correlates with late fall and winter seasons. These findings have been previously described and likely relate to the increased viral activity in these months, particularly Influenza, RSV and hMPV (Figs. 2 and 3) [10, 11, 13, 14]. This hypothesis is supported by the decreased risk observed in January, when fewer respiratory viruses are in circulation [34]. Notably, febrile seizures in children less than 1 year old were not significantly associated with any month of the year. One potential explanation for the absence of a trend in this age group is that febrile seizures occurring in this age group may be caused by non-seasonal viruses, such as HHV-6 [22].

There were four viruses in our model which were found to be positively associated with febrile seizure presentations. These were human metapneumovirus, influenza A and B, and RSV. Human metapneumovirus was positively associated with febrile seizures, with a RR of 1.19 (99% CI 1.07–1.33) in peak seasons, a strong and novel association. Human metapneumovirus infection has not been commonly described in association with febrile seizures and makes up a relatively small proportion of viral identifications in febrile seizure cohorts [10, 11]. However, hMPV has been associated with CNS illnesses ranging from seizures to encephalitis [35]. Further research is required to ascertain if a causal relationship exists between hMPV and febrile seizures, potentially focusing on the age distribution of children experiencing febrile seizures associated with hMPV infection.

Influenza viruses are recognised as an important cause of febrile seizures [19, 23, 29]. Our study has confirmed this with a 48% increase in febrile seizure incidence during peak Influenza A seasons and a 31% increase during peak Influenza B seasons, supporting previous findings that Influenza A is more strongly associated with febrile seizures [14, 29]. The strength of association between influenza and febrile seizures fluctuated in analysis of different subgroups. Influenza B was associated with a 1.37RR (99% CI 1.08–1.73) for severe febrile seizures, stronger than its association with mild febrile seizure occurrence. In general, Influenza viruses are associated with a greater proportion of complex febrile seizure presentations, though few studies have differentiated between Influenza A and B with regard to febrile seizure severity [10]. Nevertheless, given the small febrile seizure sample size in the subgroup analyses, the clinical significance of this association cannot be determined.

RSV had a distinct peak in May–July of each year, coinciding with the beginning of peak febrile seizure season. RSV is the most common cause of lower respiratory tract infections in children < 5 years old [36]. Moreover, it accounts for a significant proportion of respiratory viruses detected in children with febrile seizures [10]. RSV had a significant association with febrile seizures, with a 52% increase in risk in its peak seasons. This increase was consistent with previous findings [11, 25].

Ultimately, the goal of our study is to create a framework that depicts accurate risk of community health outcomes based on virus circulation. While the risk ratios of febrile seizures attributable to influenza viruses were approximately consistent with existing findings [20, 23], our risk ratios for RSV and hMPV were higher than those found in cohort studies of viral infections in febrile seizures [10, 11, 25]. One potential explanation for this is the abnormal influenza season observed in 2018, which had a delayed peak in October 2018–January 2019. Despite this, the peak of febrile seizures in winter 2018 was consistent with that of previous years. Our model likely attributed this to RSV and hMPV circulation which similarly maintained their trend of a winter peak. Thus, our findings highlight that there are multiple key viruses which may play a role in the occurrence of febrile seizures.

To our knowledge, this is the largest ecologic study relating febrile seizure incidence to circulating community viruses over such an extensive timeframe. The breadth of our inclusion criteria provided a sizeable dataset of both febrile seizure presentations and respiratory results. Respiratory PCR results were not restricted by age as the purpose was to estimate the local circulating community virus epidemiology for children presenting with febrile seizures. The 10-year time frame permitted sufficient data to confirm true seasonal patterns between viruses and febrile seizure presentations.

Additionally, the widespread use of multiplex PCR allowed collection of a large volume of concurrent sensitive data about numerous viruses [37, 38]. The interplay between the circulation of multiple viruses allowed...
Fig. 2  Febrile Seizure Presentations And Virus Rate 2010–2019

Fig. 3  Influenza rate and febrile seizures 2010–2019
realistic models for predicting febrile seizure incidence and the proportion attributable to specific viruses. We also determined our significance level at a low $p$-value ($p < 0.01$) to increase certainty in our findings.

The key limitation of the ecologic study design is that all associations are indirect links of febrile seizures incidence with key viruses. That is, although Influenza A and B, hMPV, and RSV circulation in the community may correlate temporally with febrile seizure presentations, our study cannot confirm that these are the causative agents associated with febrile illnesses leading to febrile seizures. In most febrile seizures presenting to emergency departments a respiratory PCR is rarely performed, and the assessment of the child usually only involves a clinical assessment to determine the cause of the seizure and rule out more sinister aetiologies [39].

The multiplex respiratory PCR performed at Monash Health sites had limitations. This PCR test does not detect HHV-6, a virus historically associated with febrile seizures. This may have been an explanatory variable for febrile seizure presentations in children less than 1 year old, which did not demonstrate a seasonal trend (Fig. 5). Additionally, our PCR assay did not differentiate between picornaviruses (i.e. enteroviruses and rhinoviruses). This made it difficult to determine the association of enterovirus and rhinovirus circulation with febrile seizures, which have been reported in previous studies [10, 11], and may have confounded our findings by leading to overestimation of the relationship between febrile seizures and the other viruses included in our model.

There was a gradual increase in the number of PCR tests performed throughout each year of our study due to changes in the clinical use of PCR testing. Therefore, we calculated positive virus results as a proportion of the total number of PCR tests performed each month to ensure the values remained relatively consistent throughout the 10-year period. While this may have masked some seasonal variation in virus circulation, this was the simplest way to create uniformity in our virus variables for the sake of analysis.

It is also important to consider that our risk ratio values were obtained based on a comparison of peak viral circulation and median viral circulation. While this allows the findings of our study to be contextualised for clinicians and public health physicians, it is difficult to relate these values to previous cohort studies. Thus, our model requires further adjustments to increase the interpretability of our findings, and future research will focus on different definitions of peak viral seasons.

Although Monash Health is the major health network providing care to children from southern and eastern Melbourne, it does not capture all emergency presentations or PCR tests from that region. As such, our datasets represented a subset from that region.

Our study has established a method for studying temporal relationships of viruses to an illness of interest using independent datasets. This methodology has implications for future studies of illnesses with undefined viral pathogenesis. The ability to estimate “attributable proportion” for specific viruses for conditions such as febrile seizures, offers the potential to inform organism specific disease burden and resultant health technology assessments for viral vaccines and therapeutics. These studies can inform healthcare practices and resource allocation and increase public awareness of the implications of specific viral infections, as has been done in Utah with GermWatch [40].

**Conclusion**

Febrile seizures are a common and clinically important illness in young children, informing future febrile and afebrile seizure risk. Our ecologic study used modern molecular viral detection technology to analyse febrile seizure temporal patterns and relationships with viruses over a 10-year period. We found that the incidence of febrile seizures doubled in winter, which was correlated with known seasonal variation in viral activity. In addition to a novel association between febrile seizures and hMPV, Influenza A, Influenza B and RSV were associated with increased febrile seizure presentations. Adenovirus, parainfluenza viruses and picornaviruses were not associated.

Our study demonstrates that we have created a model for using population-level data to relate virus circulation to health outcomes of interest. This may be particularly useful in the future for resource allocation and to assess disease-specific health outcomes, especially given the rise of novel viruses and their implications.

**Appendix A**

**Ethics**

Please see Supplementary File in submission titled “Snot-watch Protocol Version 2.0”.
Primary HREC (Monash Healthy) approval

Prof Jim Buttery
Monash Health
Department of Head, Infection and Immunity,
Director of Research, Monash Children’s Hospital
246 Clayton Rd
Clayton Vic 3168

Dear Researcher,

Study title: SNOTWATCH: Mapping real-time respiratory microbiology information to inform health outcomes

NMA/ERM Reference Number: 53611
Monash Health Ref: RES-19-000333L-53611

The Monash Health Human Research Ethics Committee Low Risk Panel has reviewed the above application. In addition, the Low Risk Panel is satisfied that the responses to our correspondence of 28 May 2019 have been sufficiently addressed.

The Low Risk Panel approved the above application on the basis of the information provided in the application form, protocol and supporting documentation. This approval is also dependant on the Authorisation from the custodian of the databases from where data is be extracted;

This reviewing Low Risk Panel is a Sub-committee of the Human Research Ethics Committee which is accredited by the Consultative Council for Clinical Trial Research under the single ethical review system.

Approval

The Low Risk Human Research Ethics approval is from 24 July 2019.

Approval is given in accordance with the research conforming to the National Health and Medical Research Council Act 1992 and the National Statement on Ethical Conduct in Human Research (2018). The HREC has ethically approved this research according to the Memorandum of Understanding between the Consultative Council and the participating organisations conducting the research.

Approval is given for this research project to be conducted at the following sites and campuses:

- Monash Health
- Alfred Health
- Department of Health Victoria
- Health Direct
- POLAR GP
- Royal Children’s Hospital
- Victorian Infectious Disease Laboratory (VIDRL)
- Ambulance Victoria (is also included in the HREA)
- Barwon Health (is also included in the HREA)
- Eastern Health
You must comply with the following conditions:

The Chief Principal Investigator is required to notify the Manager, Human Research Ethics Committees, Monash Health of:

1. Any change in protocol and the reason for that change together with an indication of ethical implications (if any)
2. Suspected Unexpected Serious Adverse Reactions (SUSARs) involving a Monash Health participant or a participant at site that Monash Health has provided HREC Review.
3. Serious Adverse Events (SAEs) that occur with a Monash Health participant or with a participant from a site that Monash Health has provided HREC review that are considered by the Investigator as being definitely related, probably related, possibly related and unknown.
4. Any unforeseen events that might affect continued ethical acceptability of the project.
5. Any expiry of the insurance coverage provided in respect of sponsored trials.
6. Discontinuation of the project before the expected date of completion, giving reasons.
7. Any change in personnel involved in the research project including any study member resigning from Monash Health &/or the study team.

At the conclusion of the project or every twelve months if the project continues, the Principal Investigator is required to complete and forward an annual progress report to the Committee.

Reminders to submit annual progress report forms will be forwarded to the researcher.

The Coordinating Principal Investigator is responsible for notifying Principal Investigators. The Coordinating Principal Investigator and Principal Investigators should forward a copy of this letter to their site’s Research Governance Officer.

Approved documents

Documents reviewed and approved are as follows:

| Document                                | Version  | Date       |
|-----------------------------------------|----------|------------|
| Human Research Ethics Application form | HREC/53611/MonH-2019-173296(v1) | 4/6/2019   |
| Study Protocol                          | 1        | 27/5/2019  |
| Victorian Specific Module               | 1        | 24/6/2019  |

Site-Specific Assessment (SSA)

SSA authorisation is required at all sites participating in the study. SSA must be authorised at a site before the research project can commence.

The completed Site-Specific Assessment Form and a copy of this ethics approval letter must be submitted to the Research Governance Officer for authorisation by the Chief Executive or delegate. This applies to each site participating in the research.

If you should have any queries about your project please contact our team via email research@monashhealth.org or via telephone 9594 4611 and request to speak with a team member.
The Low Risk Panel wishes you and your colleagues every success in your research.

Yours sincerely

DEBORAH DELL
Manager, Human Research Ethics Committee
& Research Support Services

Cc: Ms Brinda Kinakkal
Cc: Ms Gowri Selvaraj, Monash Health
Cc: Dr Chhavi Bhatt, Monash Emergency Research Collaborative

Checklist: Post-ethics approval requirements that must be met before a research project can commence at a study site.

Please ensure that as a PI (including the CPI) the following are completed at each study site.

| Requirements                                           | Yes/No/NA |
|--------------------------------------------------------|-----------|
| Ethics approval notification                           | Yes       |
| The PI must send a copy to the RGO at that study site. |           |
| HREC Review Only Indemnity                            | N/A       |
| The PI must forward a copy of the signed HREC Review Only Indemnity to the RGO at that study site. |   |
| SSA authorisation notification                        | Yes       |
| The PI must forward the SSA form and attached documents (e.g. CTRA) to the RGO so the authority approving the conduct of the trial, at that site, can complete and sign. | |
| Other Commonwealth statutory requirements              | N/A       |
| Ensure compliance with the following e.g. Office of the Gene Technology Regulator, NHMRC Licensing Committee, NHMRC Cellular Therapies Advisory Committee. | |
Appendix B Age distribution of febrile seizure incidence

![Febrile Seizures by Age](image)

**Fig. 4** Number of febrile seizure presentations in each age group

Appendix C Number of respiratory PCR tests performed each year

**Table 3** Number of each virus positive PCR and the total tests 2010–2019

| Virus          | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|----------------|------|------|------|------|------|------|------|------|------|------|
| Adenovirus     | 232  | 217  | 154  | 184  | 253  | 255  | 283  | 294  | 347  | 436  |
| hMPV           | 133  | 164  | 156  | 138  | 239  | 303  | 309  | 354  | 480  | 586  |
| Influenza A    | 195  | 251  | 361  | 260  | 712  | 485  | 737  | 1177 | 524  | 1904 |
| Influenza B    | 14   | 105  | 96   | 222  | 58   | 575  | 44   | 635  | 115  | 400  |
| Picornavirus   | 878  | 1014 | 1031 | 877  | 1491 | 1464 | 1539 | 1726 | 2295 | 3137 |
| Parainfluenza 1| 30   | 7    | 45   | 14   | 94   | 21   | 107  | 47   | 156  | 32   |
| Parainfluenza 2| 11   | 27   | 14   | 29   | 5    | 53   | 17   | 51   | 19   | 98   |
| Parainfluenza 3| 119  | 161  | 139  | 137  | 145  | 273  | 230  | 332  | 349  | 542  |
| RSV            | 442  | 393  | 439  | 376  | 548  | 577  | 686  | 856  | 888  | 1008 |
| All Viruses    | 2054 | 2339 | 2435 | 2237 | 3545 | 4006 | 3952 | 5472 | 5173 | 8143 |
| Total Tests Performed | 2960 | 4168 | 4700 | 4615 | 7920 | 9426 | 11,475 | 14,617 | 14,099 | 19,893 |
Appendix D Febrile seizure presentations in each age group by month of year

![Febrile Seizures in each age group by Month of Year](image)

**Febrile Seizures in each age group by Month of Year**

*Fig. 5* Febrile seizure seasonal trends vary in each age group

Appendix E Subgroup poisson models

**Analysis of mild febrile seizures**

**Table 4** Risk of mild febrile seizures by month of year

| Month          | Risk Ratio | 99% CI   | P-value |
|----------------|------------|----------|---------|
| January        | 0.72       | 0.56, 0.93 | 0.001   |
| February       | 0.80       | 0.63, 1.03 | 0.023   |
| March          | 0.89       | 0.70, 1.13 | 0.21    |
| April (Reference) | 1.00   | –          | –       |
| May*           | 1.33       | 1.07, 1.65 | 0.0008  |
| June*          | 1.67       | 1.36, 2.06 | <0.0001 |
| July*          | 1.76       | 1.44, 2.17 | <0.0001 |
| August*        | 1.92       | 1.57, 2.35 | <0.0001 |
| September*     | 1.85       | 1.51, 2.26 | <0.0001 |
| October*       | 1.27       | 1.02, 1.58 | 0.0053  |
| November       | 1.09       | 0.86, 1.36 | 0.35    |
| December       | 1.05       | 0.83, 1.32 | 0.59    |

*Intercept denotes estimated number of mild febrile seizures in April. Statistically significant months are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 24.4

**Table 5** Risk of mild febrile seizure presentations associated with respiratory viruses

| Virus            | 95% vs 50% Incidence | 99% CI   | P-value |
|------------------|-----------------------|----------|---------|
| Adenovirus       | 1.03                  | 0.95, 1.13 | 0.36    |
| hMPV*            | 1.18                  | 1.04, 1.34 | 0.00091 |
| Influenza A*     | 1.50                  | 1.32, 1.72 | <0.0001 |
| Influenza B*     | 1.30                  | 1.15, 1.47 | <0.0001 |
| Parainfluenza 1  | 0.94                  | 0.77, 1.14 | 0.41    |
| Parainfluenza 2  | 0.99                  | 0.88, 1.11 | 0.83    |
| Parainfluenza 3  | 1.04                  | 0.90, 1.20 | 0.47    |
| Picornavirus     | 1.07                  | 0.92, 1.23 | 0.26    |
| RSV*             | 1.53                  | 1.36, 1.73 | <0.0001 |

*Intercept denotes estimated number of mild febrile seizures per month. Statistically significant viruses are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 15.3

Analysis of severe febrile seizures
### Table 6  Risk of severe febrile seizures by month of year

| Month         | Risk Ratio | 99% CI      | P-value |
|---------------|------------|-------------|---------|
| January       | 0.72       | 0.42, 1.24  | 0.12    |
| February      | 1.13       | 0.70, 1.83  | 0.51    |
| March         | 1.15       | 0.71, 1.85  | 0.46    |
| April (Reference) | 1.00  | –          | –       |
| May           | 1.54       | 0.98, 2.41  | 0.014   |
| June*         | 2.17       | 1.42, 3.31  | <0.0001 |
| July*         | 2.06       | 1.34, 3.15  | <0.0001 |
| August*       | 2.54       | 1.68, 3.34  | <0.0001 |
| September*    | 2.43       | 1.60, 3.68  | <0.0001 |
| October*      | 1.91       | 1.24, 2.94  | 0.0011  |
| November      | 1.46       | 0.93, 2.31  | 0.031   |
| December      | 1.50       | 0.95, 2.36  | 0.021   |

Intercept denotes estimated severe number of febrile seizures in April. Statistically significant months are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 5.2.

### Table 7  Risk of severe febrile seizure presentations associated with respiratory viruses

| Virus          | 95% vs 50% Incidence Risk | 99% CI   | P-value |
|----------------|----------------------------|----------|---------|
| Adenovirus     | 0.93                       | 0.80, 1.09 | 0.24    |
| Influenza A*   | 1.47                       | 1.16, 1.86 | <0.0001 |
| Influenza B*   | 1.37                       | 1.08, 1.73 | <0.0001 |
| Parainfluenza 1| 0.93                       | 0.64, 1.35 | 0.62    |
| Parainfluenza 2| 0.79                       | 0.63, 1.00 | 0.0095  |
| Parainfluenza 3| 1.12                       | 0.88, 1.42 | 0.22    |
| Picornavirus   | 1.04                       | 0.81, 1.33 | 0.68    |
| RSV*           | 1.55                       | 1.25, 1.94 | <0.0001 |

Intercept denotes estimated number of severe febrile seizures per month. Statistically significant viruses are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 4.7.

### Table 8  Risk of febrile seizures in children < 1 year old by month of year

| Month         | Risk Ratio | 99% CI      | P-value |
|---------------|------------|-------------|---------|
| January       | 0.85       | 0.46, 1.56  | 0.48    |
| February      | 0.92       | 0.51, 1.67  | 0.73    |
| March         | 0.74       | 0.40, 1.40  | 0.23    |
| April (Reference) | 1.00  | –          | –       |
| May           | 1.05       | 0.59, 1.87  | 0.82    |
| June          | 1.13       | 0.64, 1.99  | 0.58    |
| July          | 1.26       | 0.72, 2.18  | 0.29    |
| August        | 1.26       | 0.72, 2.18  | 0.29    |
| September     | 1.31       | 0.75, 2.26  | 0.21    |
| October       | 1.10       | 0.62, 1.95  | 0.66    |
| November      | 1.03       | 0.57, 1.83  | 0.91    |
| December      | 0.72       | 0.38, 1.36  | 0.18    |

Intercept denotes estimated number of febrile seizures in this age group in April. The baseline monthly number of febrile seizures for this subgroup was 4.28.

### Table 9  Risk of febrile seizures in children < 1 year old associated with respiratory viruses

| Virus          | 95% vs 50% Incidence Risk | 99% CI   | P-value |
|----------------|----------------------------|----------|---------|
| Adenovirus     | 1.03                       | 0.81, 1.30 | 0.79    |
| Influenza A    | 1.16                       | 0.82, 1.64 | 0.27    |
| Influenza B    | 1.13                       | 0.81, 1.58 | 0.35    |
| Parainfluenza 1| 1.24                       | 0.93, 1.67 | 0.054   |
| Parainfluenza 2| 1.15                       | 0.73, 1.81 | 0.43    |
| Parainfluenza 3| 1.04                       | 0.77, 1.40 | 0.73    |
| Picornavirus   | 0.89                       | 0.61, 1.30 | 0.42    |
| RSV            | 0.84                       | 0.64, 1.10 | 0.096   |
| RSV*           | 1.07                       | 0.76, 1.51 | 0.63    |

Intercept denotes the estimated number of febrile seizures in this age group per month. The baseline monthly number of febrile seizures for this subgroup was 4.3.

Analysis of febrile seizures in children 1–2 years old
### Table 10: Risk of febrile seizures in children 1–2 years old by month of year

| Month       | Risk Ratio | 99% CI     | P-value   |
|-------------|------------|------------|-----------|
| January*    | 0.65       | 0.49, 0.86 | < 0.0001  |
| February    | 0.78       | 0.60, 1.02 | 0.17      |
| March       | 0.92       | 0.71, 1.18 | 0.38      |
| April (Reference) | 1.00 | –         | –         |
| May*        | 1.33       | 1.05, 1.67 | 0.0018    |
| June*       | 1.68       | 1.34, 2.10 | < 0.0001  |
| July*       | 1.80       | 1.44, 2.24 | < 0.0001  |
| August*     | 1.91       | 1.54, 2.37 | < 0.0001  |
| September*  | 1.85       | 1.49, 2.30 | < 0.0001  |
| October*    | 1.37       | 1.09, 1.73 | 0.00042   |
| November    | 1.06       | 0.83, 1.35 | 0.54      |
| December    | 1.16       | 0.92, 1.48 | 0.10      |

Intercept denotes estimated number of febrile seizures in this age group in April. Statistically significant months are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 21.9

### Table 11: Risk of febrile seizures in children 1–2 years old associated with respiratory viruses

| Virus       | 75% vs 25% Incidence Risk | 99% CI     | P-value   |
|-------------|---------------------------|------------|-----------|
| Adenovirus  | 1.01                      | 0.92, 1.10 | 0.83      |
| hMPV*       | 1.18                      | 1.03, 1.35 | 0.0015    |
| Influenza A*| 1.52                      | 1.32, 1.75 | < 0.0001  |
| Influenza B*| 1.25                      | 1.09, 1.42 | < 0.0001  |
| Parainfluenza 1 | 0.95          | 0.77, 1.16 | 0.49      |
| Parainfluenza 2 | 0.91          | 0.81, 1.04 | 0.067     |
| Parainfluenza 3 | 1.08          | 0.94, 1.25 | 0.16      |
| Picornavirus | 1.04                      | 0.89, 1.21 | 0.56      |
| RSV*        | 1.58                      | 1.39, 1.79 | < 0.0001  |

Intercept denotes the estimated number of febrile seizures in this age group per month. Statistically significant viruses are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 14.5

### Table 12: Risk of febrile seizures in children 3–5 years old by month of year

| Month       | Risk Ratio | 99% CI     | P-value   |
|-------------|------------|------------|-----------|
| January     | 1.03       | 0.57, 1.83 | 0.091     |
| February    | 1.28       | 0.74, 2.22 | 0.24      |
| March       | 1.18       | 0.67, 2.07 | 0.045     |
| April (Reference) | 1.00 | –         | –         |
| May*        | 1.77       | 1.06, 2.96 | < 0.0044  |
| June*       | 2.87       | 1.78, 4.64 | < 0.0001  |
| July*       | 2.56       | 1.58, 4.17 | < 0.0001  |
| August*     | 3.49       | 2.18, 5.57 | < 0.0001  |
| September*  | 3.00       | 1.86, 4.83 | < 0.0001  |
| October*    | 1.74       | 1.04, 2.93 | 0.0056    |
| November*   | 1.74       | 1.04, 2.93 | 0.0056    |
| December    | 1.44       | 0.84, 2.46 | 0.083     |

Intercept denotes estimated number of febrile seizures in this age group in April. Statistically significant months are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 3.9

### Table 13: Risk of febrile seizures in children 3–5 years old associated with respiratory viruses

| Virus       | 95% vs 50% Incidence Risk | 99% CI     | P-value   |
|-------------|---------------------------|------------|-----------|
| Adenovirus  | 0.83                      | 0.67, 1.04 | 0.03      |
| hMPV        | 1.17                      | 0.91, 1.51 | 0.0990    |
| Influenza A*| 1.54                      | 1.20, 1.98 | < 0.0001  |
| Influenza B*| 1.44                      | 1.13, 1.84 | < 0.0001  |
| Parainfluenza 1 | 0.78          | 0.51, 1.19 | 0.13      |
| Parainfluenza 2 | 0.94          | 0.74, 1.20 | 0.52      |
| Parainfluenza 3 | 1.13          | 0.86, 1.49 | 0.26      |
| Picornavirus | 0.88                      | 0.69, 1.14 | 0.21      |
| RSV         | 1.67                      | 1.31, 2.12 | < 0.0001  |

Intercept denotes the estimated number of febrile seizures in this age group per month. Statistically significant viruses are denoted with *. The baseline monthly number of febrile seizures for this subgroup was 5.3
Abbreviations
CI: Confidence Interval; CNS: Central Nervous System; ED: Emergency Department; ERM: Ethical Review Manager; HHV-6: Human Herpesvirus-6; hMPV: Human Metapneumovirus; HREC: Human Research Ethics Committee; ICD-10 AM: International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification; MOY: Month of Year; NMA: National Mutual Acceptance; PCR: Polymerase Chain Reaction; RR: Risk Ratio; RSV: Respiratory Syncytial Virus; URN: Unit Record Number; URTIs: Upper Respiratory Tract Infections.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12887-022-03222-4.

Additional file 1.

Acknowledgements
Not applicable.

Authors’ contributions
R.S. contributed to the conceptualisation of the study, wrote the main manuscript of the text, prepared all figures and tables in the text, developed and conducted all statistical analysis, and reviewed and edited the final manuscript. M. K assisted in the development of the statistical methodology, and reviewed and edited the final manuscript. M.F., H.C. and J.B. contributed to the conceptualisation of the study, supervised of the project, and reviewed and edited the final manuscript. The author(s) read and approved the final manuscript.

Funding
Royal Children’s Hospital Foundation (Buttery research allocation).

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Declarations
Ethics approval and consent to participate
As per our study protocol (Appendix A), a waiver of informed consent was sought, as all patient data was de-identified and could not be traced back to the patients. All methods for this ecological study were carried out in accordance with the relevant guidelines and regulations. The informed consent waiver was provided by Monash Health Human Research Ethics Committee (HREC). This was obtained beginning 24th July 2019 (NMA/ERM Reference Number: RES-19-000333-L-53611). Ethical approval through our primary Human Research Ethics Committee (HREC) was obtained in Monash Health from 24th July 2019 (NMA/ERM Reference Number: RES-19-000333-L-53611). See Appendix A.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interests.

Author details
1Department of Paediatrics, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia. 2Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia. 3Division of Pharmacoeconomics and Pharmacoeconomics, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, USA. 4Department of Neurology, Monash Children’s Hospital, Clayton, Victoria, Australia. 5Neurogenetics Department, Monash Paediatrics, Monash University, Clayton, Victoria, Australia. 6School of Population & Global Health, University of Melbourne, Parkville, Victoria, Australia. 7Child Health Informatics, Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.

Received: 4 November 2021 Accepted: 15 March 2022
Published online: 22 June 2022

References
1. Canpolat M, Per H, Gumus H, Elmali F, Kumandas S. Investigating the prevalence of febrile convulsion in Kayseri, Turkey: an assessment of the risk factors for recurrence of febrile convulsion and for development of epilepsy. Seizure. 2018;55:36–47.
2. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975;16(1):1–66.
3. Verburgh ME, Bruijnzeels MA, van der Wouden JC, et al. Incidence of febrile seizures in The Netherlands. Neuroepidemiology. 1992;11(4–6):169–72.
4. Forsgren L, Sidenvall R, Blomquist HK, Heijbel J. A prospective incidence study of febrile convulsions. Acta Paediatr Scand. 1990;79(5):550–7.
5. Subcommittee on Febrile Seizures, American Academy of Pediatrics. Neurodiagnostic evaluation of the child with a simple febrile seizure Pediatrics. 2011;127(2):389-394. https://doi.org/10.1542/peds.2010-3318.
6. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia. 1989;30(4):389-399. https://doi.org/10.1111/j.1528-1157.1989.tb00316.x.
7. Manurkar P, Herrin E, Satnis C. Predictive factors for recurrent febrile seizures in children. Paediatr Indones. 2012;52:317.
8. Verity CM, Golding J. Risk of epilepsy after febrile convulsions: a national cohort study. BMJ. 1991;303(6814):1373–6.
9. Berg AT, Shinnar S. Complex febrile seizures. Epilepsia. 1996;37(2):126–33.
10. Francis JR, Richmond P, Robins C, et al. An observational study of febrile seizures: the importance of viral infection and immunization. BMC Pediatr. 2016;16(1):202.
11. Pokorn M, Jevnik M, Petrovec M, et al. Respiratory and enteric virus detection in children. J Child Neurol. 2017;32(3):84–93.
12. Lewis HM, Parry JV, Parry RP, et al. Role of viruses in febrile convulsions. Arch Dis Child. 1979;54(11):869–76.
13. Stokes MJ, Downham MA, Webb JK, McQuillim J, Gardner PS. Viruses and febrile convulsions. Arch Dis Child. 1977;52(2):129–33.
14. Carman KB, Callik M, Karal Y, et al. Viral etiological causes of febrile seizures for respiratory pathogens (EFES Study). Hum Vaccin Immunother. 2019;15(2):496–502.
15. Shah SS, Alpem ER, Zwerling L, Reid JR, McGowan KL, Bell LM. Low risk of bacteremia in children with febrile seizures. Arch Pediatr Adolesc Med. 2002;156(5):469–72.
16. Manfredini R, Vergine G, Boari B, Faggioni R, Borgna-Pignatti C. Circadian and seasonal variation of first febrile seizures. J Pediatr. 2004;145(6):838–9.
17. Mikkonen K, Uhan M, Pokka T, Rantalainen H. Diurnal and seasonal occurrence of febrile seizures. Pediatr Neurol. 2013;52(4):424–7.
18. Millichap JJ, Gordon MJ. Methods of investigation and management of infections causing febrile seizures. Pediatr Neurol. 2008;39(6):381–6.
19. van Zeijl JH, Mullaart RA, Borm GF, Galama JM. Recurrence of febrile seizures in the respiratory season is associated with influenza A. J Pediatr. 2004;145(6):800–5.
20. Han DH, Kim SY, Lee NM, et al. Seasonal distribution of febrile seizure and the relationship with respiratory and enteric viruses in Korean children based on nationwide registry data. Seizure. 2019;73:13–17.
21. Polkinghome BS, Mucalottio DJ, Macintyre CR, Lawrence GL, Middleton PM, Torvaldsen S. Relationship between the population incidence of febrile convulsions in young children in Sydney, Australia and seasonal epidemics of influenza and respiratory syncytial virus, 2003–2010: a time series analysis. BMC Infect Dis. 2011;11:291.
22. Suga S, Suzuki K, Iriha M, et al. Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child. 2000;82(1):62–6.
23. Chiu SS, Tse CY, Lau YL, Peiris M. Infection with influenza A infection is an important cause of febrile seizures. Pediatrics. 2001;108(4):E63.
24. Meury S, Zeller S, Heininger U. Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents. Eur J Pediatr. 2004;163(7):359–63.
25. Chung B, Wong V. Relationship between five common viruses and febrile seizure in children. Arch Dis Child. 2007;92(7):589–93.
26. Millichap JG, Millichap JJ. Role of viral infections in the etiology of febrile seizures. Pediatr Neurol. 2006;35(3):165–72.
27. Yun SG, Kim MY, Choi JM, et al. Comparison of three multiplex PCR assays for detection of respiratory viruses: Anyplex II RV16, AdvanSure RV, and Real-Q RV. J Clin Lab Anal. 2018;32(2):e2230. https://doi.org/10.1002/jcla.22230.
28. Downham MA, McQuillan J, Gardner PS. Diagnosis and clinical significance of parainfluenza virus infections in children. Arch Dis Child. 1974;49(1):8-15. https://doi.org/10.1136/adc.49.1.8.
29. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003;36(3):299–305.
30. Tsuboi T, Okada S. Seasonal variation of febrile convulsion in Japan. Acta Neurol Scand. 1984;69(5):285–92.
31. Monash Health- Annual Report 2018–2019. Australia: Monash Health;2018–2019.
32. R: A language and environment for statistical computing (computer program). Vienna: R Foundation for Statistical Computing; 2010.
33. RStudio Team. RStudio: Integrated Development Environment for R [Internet]. Boston, MA; 2015. Available from: http://www.rstudio.com/.
34. Price OH, Sullivan SG, Sutterby C, Druce J, Carville KS. Using routine testing data to understand circulation patterns of influenza A, respiratory syncytial virus and other respiratory viruses in Victoria, Australia. Epidemiol Infect. 2019;147:e221.
35. Arnold JC, Singh KK, Milder E, et al. Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J. 2009;28(12):1057–60.
36. Hačmustafaoğlu M, Celebi S, Bozdemir SE, et al. RSV frequency in children below 2 years hospitalized for lower respiratory tract infections. Turk J Pediatr. 2013;55(2):130–9.
37. Liao RS, Tomalty LL, Majury A, Zoutman DE. Comparison of viral isolation and multiplex real-time reverse transcription-PCR for confirmation of respiratory syncytial virus and influenza virus detection by antigen immunoassays. J Clin Microbiol. 2009;47(3):527–32.
38. Wolfs PF, Bruggeman CA, van Well GT, van Loo IH. Replacing traditional diagnostics of fecal viral pathogens by a comprehensive panel of real-time PCRs. J Clin Microbiol. 2011;49(5):1526–31.
39. Smith DK, Sadler KP, Benedum M. Febrile seizures: risks, evaluation, and prognosis. Am Fam Physician. 2019;99(7):445–50.
40. Healthcare I. GermWatch. https://intermountainhealthcare.org/health-information/germwatch/. Published 2021. Accessed Jul 2021.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.